Famdenovo

Famdenovo predicts whether a germline mutation in a family is de novo versus familial to identify de novo mutation carriers in inherited cancer syndromes such as Li-Fraumeni syndrome.

Key Features:

• Pedigree-Based Prediction: Uses detailed family pedigree information to calculate the likelihood that a germline mutation is de novo.
• Statistical Accuracy: Demonstrates a concordance index of 0.95 (95% CI: [0.92, 0.98]) for Famdenovo.TP53 in predicting de novo mutation (DNM) status among Li-Fraumeni syndrome families.
• Application to Multiple Syndromes: Implements specific models such as Famdenovo.TP53 for TP53 and Famdenovo.BRCA for BRCA-related hereditary breast and ovarian cancer.
• Comprehensive Analysis: Compares clinical and biological features between familial mutation (FM) and DNM carriers, including cancer and mutation spectra, parental ages, and ascertainment criteria like early-onset breast cancer.
• Insights into Mutation Dynamics: Detects differences in mutation spectra between DNMs and FMs, for example the absence of hotspot R248W in TP53 among observed DNMs.

Scientific Applications:

• Research: Enables identification of DNM carriers to study molecular mechanisms driving de novo mutations and their role in cancer etiology and progression.
• Clinical Management: Informs risk assessment and management strategies in families with inherited cancer syndromes by distinguishing DNMs from FMs.

Methodology:

Integrates pedigree-based prediction models with statistical analysis of family history and mutation data to compute the probability that a germline mutation is de novo and refines models by analyzing large cohorts of family pedigrees.